Dermatology

Your daily dose of the clinical news you may have missed.

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.